EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An observation of weight gain in patients with atopic dermatitis receiving dupilumab

Darren Roche, Donal O'Shea, Brian Kirby, Ali Alsharqi

Clinical and Experimental Dermatology · 2025

DOI: 10.1093/ced/llaf292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Darren Roche und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tallaght University Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Weight Gain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis (AD) is a chronic inflammatory skin condition driven by immune dysregulation, particularly T helper 2-mediated cytokines such as interleukin (IL) 4 and IL-13. Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit, has emerged as an effective therapy for moderate-to-severe AD. However, emerging evidence suggests a potential association between dupilumab and weight gain, likely due to the metabolic role of IL-4.

Objectives

To evaluate weight changes in patients with AD undergoing dupilumab therapy.

Methods

We conducted a retrospective chart review of patients who were prescribed dupilumab between April 2018 and December 2023. Inclusion criteria required dupilumab treatment for > 6 months with documented weight measurements within 3 months before treatment initiation and at 3–6 months after initiation. Thirty patients met inclusion criteria. Demographic data, prior treatments, disease severity and weight changes were analysed.

Results

Of the 30 patients, 21 were men and 9 were women, with a mean age of 40.1 years. The mean (SD) baseline weight was 81.5 (17.3) kg. Twenty patients (67%) experienced weight gain, with a mean increase of 5.9 (3.3) kg. Seven patients (23%) had no weight change, and three (10%) lost weight [mean loss 3.7 (3.8) kg]. The overall mean weight gain was 3.6 (4.5) kg.

Conclusions

Our findings suggest that dupilumab treatment in AD may be associated with weight gain in a subset of patients. Given the emerging role of IL-4 in metabolic regulation, further prospective studies are warranted to clarify the mechanism and clinical significance of this potential adverse effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedWeight GainHumansFemaleMaleAdultRetrospective StudiesMiddle AgedInterleukin-4Interleukin-4 Receptor alpha Subunit

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedInterleukin-4Interleukin-4 Receptor alpha Subunit

Autor:innen und Institutionen

  • Department of Dermatology, Tallaght University Hospital, Dublin, Ireland.
  • Department of Endocrinology, St Vincent's University Hospital, Dublin, Ireland.
  • Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland.
  • Charles Institute of Dermatology, University College Dublin, Belfield, Dublin, Ireland.

Zitieren

APA

Roche, D., O'Shea, D., Kirby, B., & Alsharqi, A. (2025). An observation of weight gain in patients with atopic dermatitis receiving dupilumab. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf292

Vancouver

Roche D, O'Shea D, Kirby B, Alsharqi A. An observation of weight gain in patients with atopic dermatitis receiving dupilumab. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf292

BibTeX
@article{Roche2025,
  author = {Roche, Darren and O'Shea, Donal and Kirby, Brian and Alsharqi, Ali},
  title = {An observation of weight gain in patients with atopic dermatitis receiving dupilumab},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  doi = {10.1093/ced/llaf292}
}
Kostenlos starten →